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Ivabradine selectively reduces heart rate (HR) 
by inhibiting If of the sinus node. The BEAUTI-
FUL trial has shown that ivabradine is ‘beneficial’ 
in patients who suffered from coronary artery 
disease (CAD) with systolic heart failure (HF) 
(ejection fraction [EF] 32%) without evidence of 
overt HF. Added to standard therapy ivabradine did 
not significantly the primary composite endpoint 
(admission to hospital for new onset or worsening 
HF, admission to hospital for acute myocardial 
infarction or cardiovascular death); however, in 
a subgroup of patients with baseline HR > 70 bpm 
(mean 79 bpm) ivabradine significantly decreased 
(–36%) the risk for fatal and non-fatal acute myo-
cardial infarction, and (–30%) the risk of coronary 
revascularization [1].
In the SHIFT trial patients with systolic HF 
(EF < 35%), mainly class New York Heart Asso-
ciation (NYHA) II–III and HR > 70 bpm, and who 
received optimized background therapy accord-
ing to guideline recommendations were treated 
with ivabradine or placebo. A higher HR ≥ 75 bpm 
at entry, there was a significant reduction in the 
cardiovascular death and all-cause mortality end-
points [2]. Patients on ivabradine with an HR 
reduction (11 bpm) had an 18% decrease of com-
posite endpoint; this result was primarily driven 
by a reduction (–26%) in hospital admissions for 
worsening HF [3, 4].
In patients with HF, due to ischemic etiology 
with left ventricular diastolic dysfunction and 
preserved systolic function ivabradine is poorly 
effective [5].
Importantly, in the SIGNIFY trial, in patients 
who had stable CAD (Canadian Cardiovascular 
Society [CCS] class ≥ 2) without clinical HF, and 
who were treated with guideline-recommended 
medical therapy, the addiction of ivabradine did 
not improve the outcome; furthermore, adverse 
events occurred statistically (p < 0.001 for all 
class comparisons) more frequently with ivabradine 
than with placebo [6]. Adverse events led to study-
drug withdrawal in 13.2% of the ivabradine-group 
and in 7.4% of the placebo group (p < 0.001) [2]. 
Ivabradine significantly increased the frequency 
of symptomatic bradycardia, atrial fibrillation and 
phosphenes.
Ivabradine is generally considered to be safe 
[7, 8]. However, in patients with stable CAD, when 
added to other drugs such as beta-blockers, the drug 
may induce severe bradycardia and increase the 
occurrence of atrial fibrillation [6]. Furthermore, at 
least in patients with a long QT ivabradine has the 
potential for the occurrence for the occurrence of 
torsades de pointes [9].
In the present issue of the journal, Ordu et al. 
[10] report the findings of a prospective, open-label 
study in 98 outpatients with stable systolic HF 
(LVEF < 35%). The study had a two-arm design. 
Patients received optimized background therapy 
according to guideline recommendations. Ivabra-
dine (average dose 10 ± 3 mg/day) or placebo 
was added for 6 months. Ivabradine significantly 
decreased the NYHA class and HR from 84 ± 8.8 
to 68 ± 8.3 bpm. The authors assessed the effect 
of ivabradine on cystatin C, CA-125 and N-terminal 
of the prohormone B-type natriuretic peptide (NT-
-proBNP). The three biomarkers decreased sig-
nificantly (p = 0.001 in comparison with placebo).
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Cystatin C decreased from 2.1 ± 0.7 to 1.5 ± 
± 0.4 ml/L. It is established that renal dysfunction 
is frequent in HF and, when present, is associated 
with higher mortality and morbidity [11]. The 
decrease of cystatin C might be interpreted as 
evidence that renal dysfunction decreased, thus 
improving cardiovascular outcomes. Unfortunately, 
the values at the end of the study were still el-
evated (1.5 ± 0.4 mg/L) and, as well demonstrated 
by Shlipak et al. [12], the risk for all cause of death 
remained very high.
Ordu et al. [10] also measured CA-125, which 
decreased from 31 ± 21 to 13± 8 U/L. CA-125 is 
not a ‘cardiac’ marker: it has limited specificity for 
ovarian cancer, may be elevated in a number of 
conditions, and in the presence of any inflamma-
tory condition in the abdominal area as well as in 
cirrhosis and diabetes mellitus [13]. The ‘normal’ 
level for CA-125 is considered to be up to 35 U/mL. 
CA-125 values were normal before and after ivabra-
dine. Even if the decrease was statistically signifi-
cant, one cannot explain how the observed minor 
decrease might interact with cardiac outcomes.
NT-proBNP is a well-known cardiac marker 
which has been extensively used to assess the 
benefits of BNP-guided therapy in chronic HF [14]. 
In the study by Ordu et al. [10] NT-proBNP sig-
nificantly decreased from 1.353 ± 1.454 to 718 ± 
± 835 pg/L. However, standard deviation is greater 
than the mean value and the detected changes 
might be within the well-known spontaneous 
fluctuations observed in patients with severe 
congestive HF [14]. Perhaps ivabradine decreased 
NT-proBNP, at least in some patients. Nonethe-
less, the end-values are still much higher than the 
levels regarded as necessary to consider if medical 
therapy is adequate [14].
Several caveats also limit the authors’ find-
ings. First, the data result from a single center, the 
duration of therapy was short and the number of 
patients is too small to detect adverse effects and 
assess the effect on cardiac outcomes. Second, 16% 
of patients had cardiac pacemakers. Ivabradine, es-
pecially combined with beta-blockers, may induce 
severe bradycardia, but this adverse effect can be 
undetected in patients with a pacemaker. Third, pa-
tients had a systolic EF < 35%. Many patients (data 
are unclearly offered) had a combination of CAD, 
hypertension and diabetes mellitus. Concomitant 
pathologies are ‘real-life’ facts in patients with 
severe congestive HF. The authors did not report 
necessary data, such as the clinical conditions and 
values of blood pressure and did not report any 
adverse events. It is difficult to assess the effect 
of ivabradine in a mixed-population.
We are left with the question how ivabradine 
should optimally be used in cardiological practice. 
Given that the primary cardiovascular effect of 
ivabradine is to reduce HR, in patients who have 
stable CAD without clinical HF, an elevated HR 
might only be a marker of risk, but not a modifiable 
determinant of outcomes. Elevated HR may be 
a sign of different pathophysiological mechanisms 
in patients with HF and in those with CAD. Perhaps 
ivabradine has no effect on outcomes in patients 
with stable CAD. At least from the SIGNIFY study, 
it might be assumed that there may be a J-shaped 
curve for the relationship between HR and cardiac 
outcomes. There is a signal for an increase in the 
risk of cardiovascular events among patients with 
angina of CCS class II or higher. In some patients 
ivabradine may decrease HR too much or induce 
atrial fibrillation.
When patients who have HF due to ischemic 
etiology are treated with ivabradine, they should 
be monitored to avoid the occurrence of severe 
bradycardia and to be properly treated if atrial 
fibrillation occurs.
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